XML 122 R49.htm IDEA: XBRL DOCUMENT
v3.22.1

License Agreements - Additional Information (Details) - USD ($) |  | 1 Months Ended | 12 Months Ended
--- | --- | --- | ---
Jul. 20, 2021 | Aug. 31, 2021 | Jul. 31, 2021 | May 31, 2021 | Jan. 31, 2021 | Apr. 30, 2020 | Mar. 31, 2020 | Feb. 29, 2020 | Dec. 31, 2021 | Dec. 31, 2020
License Agreements [Line Items] |  |  |  |  |  |  |  |  |  |
In-process research and development |  |  |  |  |  |  |  |  | $ 10,848,000 | $ 71,745,000
Common Stock |  |  |  |  |  |  |  |  |  |
License Agreements [Line Items] |  |  |  |  |  |  |  |  |  |
Convertible preferred stock converted into shares of common stock |  |  |  |  |  |  |  |  | 71,263,685 |
License Agreement | NiKang Therapeutics, Inc. |  |  |  |  |  |  |  |  |  |
License Agreements [Line Items] |  |  |  |  |  |  |  |  |  |
Upfront payment |  |  |  |  |  |  |  | $ 5,000,000.0 |  |
Reimbursement of certain initial manufacturing costs |  |  |  |  |  |  |  | $ 400,000 |  |
Payment for US patent application |  |  |  |  |  | $ 7,000,000.0 |  |  |  |
Accrued development milestone payment |  |  |  |  |  |  |  |  | $ 0 | 4,000,000.0
In-process research and development |  |  |  |  |  |  |  |  | 0 | 16,000,000.0
Ownership percentage of equity or assets |  |  |  |  |  |  |  | 50.00% |  |
License Agreement | NiKang Therapeutics, Inc. | First Licensed Product | Maximum |  |  |  |  |  |  |  |  |  |
License Agreements [Line Items] |  |  |  |  |  |  |  |  |  |
Development and regulatory milestone payments obligation |  |  |  |  |  |  |  | $ 16,000,000.0 |  |
Commercial milestone payments obligation |  |  |  |  |  |  |  | 157,000,000.0 |  |
License Agreement | NiKang Therapeutics, Inc. | Second Licensed Product |  |  |  |  |  |  |  |  |  |
License Agreements [Line Items] |  |  |  |  |  |  |  |  |  |
Development and regulatory milestone payments obligation |  |  |  |  |  |  |  | 12,000,000.0 |  |
Commercial milestone payments obligation |  |  |  |  |  |  |  | $ 151,000,000.0 |  |
License Agreement | Katmai Pharmaceuticals, Inc. |  |  |  |  |  |  |  |  |  |
License Agreements [Line Items] |  |  |  |  |  |  |  |  |  |
Upfront payment |  |  |  |  |  |  | $ 5,700,000 |  |  |
In-process research and development |  |  |  |  |  |  |  |  | 0 | 5,700,000
License Agreement | Katmai Pharmaceuticals, Inc. | Series B-1 Convertible Preferred Stock and Series B-2 Convertible Preferred Stock |  |  |  |  |  |  |  |  |  |
License Agreements [Line Items] |  |  |  |  |  |  |  |  |  |
Stock issued, value |  |  |  |  |  |  | 2,700,000 |  |  |
License Agreement | Katmai Pharmaceuticals, Inc. | Series B-1 Convertible Preferred Stock |  |  |  |  |  |  |  |  |  |
License Agreements [Line Items] |  |  |  |  |  |  |  |  |  |
Stock issued, value |  |  |  |  |  | $ 1,800,000 |  |  |  |
Stock issued and sold |  |  |  |  |  | 356,000 |  |  |  |
License Agreement | Katmai Pharmaceuticals, Inc. | Series B-2 Convertible Preferred Stock |  |  |  |  |  |  |  |  |  |
License Agreements [Line Items] |  |  |  |  |  |  |  |  |  |
Stock issued, value |  |  |  |  | $ 900,000 |  |  |  |  |
Stock issued and sold |  |  |  |  | 118,666 |  |  |  |  |
License Agreement | Katmai Pharmaceuticals, Inc. | Maximum |  |  |  |  |  |  |  |  |  |
License Agreements [Line Items] |  |  |  |  |  |  |  |  |  |
Development and regulatory milestone payments obligation |  |  |  |  |  |  | 26,000,000.0 |  |  |
Commercial milestone payments obligation |  |  |  |  |  |  | 101,000,000.0 |  |  |
License Agreement | LifeArc |  |  |  |  |  |  |  |  |  |
License Agreements [Line Items] |  |  |  |  |  |  |  |  |  |
Upfront payment |  |  |  |  |  | $ 0 |  |  |  |
In-process research and development |  |  |  |  |  |  |  |  | 0 | 75,000
One-time license payment |  |  |  |  |  | 75,000 |  |  |  |
License Agreement | LifeArc | Maximum |  |  |  |  |  |  |  |  |  |
License Agreements [Line Items] |  |  |  |  |  |  |  |  |  |
Development and regulatory milestone payments obligation |  |  |  |  |  | $ 11,000,000.0 |  |  |  |
Sales milestone payments obligation |  |  |  |  |  |  | $ 50,000,000.0 |  |  |
License Agreement | The Regents |  |  |  |  |  |  |  |  |  |
License Agreements [Line Items] |  |  |  |  |  |  |  |  |  |
Upfront payment |  |  |  | $ 50,000 |  |  |  |  |  |
In-process research and development |  |  |  |  |  |  |  |  | 7,200,000 | $ 0
Sales milestone payments obligation |  |  |  | $ 2,000,000.0 |  |  |  |  |  |
Percentage of third tier sublicensing fees |  |  |  | 30.00% |  |  |  |  |  |
Cash payments in license agreement upon achievement of corporate milestone |  | $ 1,700,000 |  |  |  |  |  |  |  |
License Agreement | The Regents | Common Stock |  |  |  |  |  |  |  |  |  |
License Agreements [Line Items] |  |  |  |  |  |  |  |  |  |
Stock issued and sold |  |  |  | 944,945 |  |  |  |  |  |
License Agreement | The Regents | Maximum |  |  |  |  |  |  |  |  |  |
License Agreements [Line Items] |  |  |  |  |  |  |  |  |  |
Development and regulatory milestone payments obligation |  |  |  | $ 6,400,000 |  |  |  |  |  |
IPO |  |  |  |  |  |  |  |  |  |
License Agreements [Line Items] |  |  |  |  |  |  |  |  |  |
Stock issued, value |  |  |  |  |  |  |  |  | 316,999,000 |
IPO | Common Stock |  |  |  |  |  |  |  |  |  |
License Agreements [Line Items] |  |  |  |  |  |  |  |  |  |
Stock issued, value |  |  |  |  |  |  |  |  | $ 2,000 |
Stock issued and sold | 21,562,500 |  |  |  |  |  |  |  | 21,562,500 |
Convertible preferred stock converted into shares of common stock | 71,263,685 |  | 71,263,685 |  |  |  |  |  |  |
IPO | License Agreement | Katmai Pharmaceuticals, Inc. | Series B-1 Convertible Preferred Stock and Series B-2 Convertible Preferred Stock |  |  |  |  |  |  |  |  |  |
License Agreements [Line Items] |  |  |  |  |  |  |  |  |  |
Conversion of convertible preferred stock into common stock |  |  |  |  |  |  | 395,555 |  |  |

X
- Definition Accrued development milestone payment. + References No definition available. + Details
Name: | eras_AccruedDevelopmentMilestonePayment
Namespace Prefix: | eras_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Cash payments in license agreement upon achievement of corporate milestone. + References No definition available. + Details
Name: | eras_CashPaymentsInLicenseAgreementUponAchievementOfCorporateMilestone
Namespace Prefix: | eras_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Commercial milestone payments obligation. + References No definition available. + Details
Name: | eras_CommercialMilestonePaymentsObligation
Namespace Prefix: | eras_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Development and regulatory milestone payments obligation. + References No definition available. + Details
Name: | eras_DevelopmentAndRegulatoryMilestonePaymentsObligation
Namespace Prefix: | eras_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition License agreements. + References No definition available. + Details
Name: | eras_LicenseAgreementsLineItems
Namespace Prefix: | eras_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition One-time license payment. + References No definition available. + Details
Name: | eras_OneTimeLicensePayment
Namespace Prefix: | eras_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Ownership percentage of equity or assets. + References No definition available. + Details
Name: | eras_OwnershipPercentageOfEquityOrAssets
Namespace Prefix: | eras_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Payment related to publication of US patent application. + References No definition available. + Details
Name: | eras_PaymentRelatedToPublicationOfUSPatentApplication
Namespace Prefix: | eras_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Percentage of obligation to pay third tier sublicensing fees. + References No definition available. + Details
Name: | eras_PercentageOfObligationToPayThirdTierSublicensingFees
Namespace Prefix: | eras_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Reimbursement of certain initial manufacturing costs. + References No definition available. + Details
Name: | eras_ReimbursementOfCertainInitialManufacturingCosts
Namespace Prefix: | eras_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Sales milestone payments obligation. + References No definition available. + Details
Name: | eras_SalesMilestonePaymentsObligation
Namespace Prefix: | eras_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Upfront payment. + References No definition available. + Details
Name: | eras_UpfrontPayment
Namespace Prefix: | eras_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Number of shares issued for each share of convertible preferred stock that is converted. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(27)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 16 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 6 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644 + Details
Name: | us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition. + References No definition available. + Details
Name: | us-gaap_ResearchAndDevelopmentInProcess
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Number of shares issued during the period as a result of the conversion of convertible securities. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29-30) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 20 -Section 50 -Paragraph 1E -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644 + Details
Name: | us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of new stock issued during the period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_StockIssuedDuringPeriodSharesNewIssues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_StockIssuedDuringPeriodValueNewIssues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=eras_LicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=eras_NiKangTherapeuticsIncorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=eras_FirstLicensedProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=eras_SecondLicensedProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=eras_KatmaiPharmaceuticalsIncorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementClassOfStockAxis=eras_SeriesB1ConvertiblePreferredStockAndSeriesB2ConvertiblePreferredStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementClassOfStockAxis=eras_SeriesB1ConvertiblePreferredStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementClassOfStockAxis=eras_SeriesB2ConvertiblePreferredStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=eras_LifeArcMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=eras_TheRegentsOfUniversityOfCaliforniaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |